Abstract
Subjects (109) with symptomatic Paget's disease of bone were treated with 5, 10, or 20 mg of sodium etidronate (EHDP)/kg body weight/day for 6 to 24 mth. Significant decreases in serum alkaline phosphatase and urinary hydroxyproline were noted after 6 mth of therapy; no significant further improvement resulted after prolonged therapy. Some patients maintained biochemical remission after withdrawal of EHDP but others showed a relapse, related primarily to the pretreatment severity. Clinical improvement was noted in 61% of the patients. Similar findings were seen after a second course of EHDP. No side-effects were noted in patients treated with 5 mg of EHDP/kg body weight/day. In patients treated with 10 or 20 mg of EHDP/kg body weight/day, severe diarrhea, bone pain, and nontraumatic fractures were noted in 3, 13, and 12 patients respectively. Quantitative histomorphometry showed mineralization delay in patients receiving 10 or 20 mg of EHDP/kg body weight/day but not in those receiving 5 mg/kg body weight/day. Five milligrams of EHDP/kg body weight/day was effective and appears to be safer than the higher doses.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 656-663 |
| Number of pages | 8 |
| Journal | Annals of Internal Medicine |
| Volume | 87 |
| Issue number | 6 |
| State | Published - 1977 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results. / Khairi, M. R A; Altman, Roy D; DeRosa, G. P.; Zimmermann, J.; Schenk, R. K.; Johnston, C. C.
In: Annals of Internal Medicine, Vol. 87, No. 6, 1977, p. 656-663.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results
AU - Khairi, M. R A
AU - Altman, Roy D
AU - DeRosa, G. P.
AU - Zimmermann, J.
AU - Schenk, R. K.
AU - Johnston, C. C.
PY - 1977
Y1 - 1977
N2 - Subjects (109) with symptomatic Paget's disease of bone were treated with 5, 10, or 20 mg of sodium etidronate (EHDP)/kg body weight/day for 6 to 24 mth. Significant decreases in serum alkaline phosphatase and urinary hydroxyproline were noted after 6 mth of therapy; no significant further improvement resulted after prolonged therapy. Some patients maintained biochemical remission after withdrawal of EHDP but others showed a relapse, related primarily to the pretreatment severity. Clinical improvement was noted in 61% of the patients. Similar findings were seen after a second course of EHDP. No side-effects were noted in patients treated with 5 mg of EHDP/kg body weight/day. In patients treated with 10 or 20 mg of EHDP/kg body weight/day, severe diarrhea, bone pain, and nontraumatic fractures were noted in 3, 13, and 12 patients respectively. Quantitative histomorphometry showed mineralization delay in patients receiving 10 or 20 mg of EHDP/kg body weight/day but not in those receiving 5 mg/kg body weight/day. Five milligrams of EHDP/kg body weight/day was effective and appears to be safer than the higher doses.
AB - Subjects (109) with symptomatic Paget's disease of bone were treated with 5, 10, or 20 mg of sodium etidronate (EHDP)/kg body weight/day for 6 to 24 mth. Significant decreases in serum alkaline phosphatase and urinary hydroxyproline were noted after 6 mth of therapy; no significant further improvement resulted after prolonged therapy. Some patients maintained biochemical remission after withdrawal of EHDP but others showed a relapse, related primarily to the pretreatment severity. Clinical improvement was noted in 61% of the patients. Similar findings were seen after a second course of EHDP. No side-effects were noted in patients treated with 5 mg of EHDP/kg body weight/day. In patients treated with 10 or 20 mg of EHDP/kg body weight/day, severe diarrhea, bone pain, and nontraumatic fractures were noted in 3, 13, and 12 patients respectively. Quantitative histomorphometry showed mineralization delay in patients receiving 10 or 20 mg of EHDP/kg body weight/day but not in those receiving 5 mg/kg body weight/day. Five milligrams of EHDP/kg body weight/day was effective and appears to be safer than the higher doses.
UR - http://www.scopus.com/inward/record.url?scp=0017587282&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017587282&partnerID=8YFLogxK
M3 - Article
C2 - 412450
AN - SCOPUS:0017587282
VL - 87
SP - 656
EP - 663
JO - Annals of Internal Medicine
JF - Annals of Internal Medicine
SN - 0003-4819
IS - 6
ER -